CardioSignal
Provides world-leading solutions for the detection of complex and life-threatening cardiac conditions using its proprietary patent-protected technology, enabling fast and reliable cardiac analysis using just a regular smartphone.
Launch date
Employees
Market cap
-
Enterprise valuation
€36—55m (Dealroom.co estimates Jan 2024.)
Company register number 2800927-7
Turku Southwest Finland (HQ)
Financials
Estimates*
| EUR | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Revenues | - | <1m | <1m | <1m | <1m | <1m |
| % growth | - | - | 600 % | 986 % | 44 % | 4 % |
| EBITDA | (<1m) | <1m | (<1m) | (1.4m) | - | - |
| % EBITDA margin | - | 5233 % | (686 %) | (634 %) | - | - |
| Profit | (<1m) | <1m | (<1m) | (1.6m) | - | - |
| % profit margin | - | 1467 % | (1338 %) | (696 %) | - | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
€2.0m | Grant | ||
| N/A | €2.2m | Seed | |
€2.2m | Seed | ||
* | $10.0m | Series A | |
| Total Funding | €15.5m | ||
Recent News about CardioSignal
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.